The resistance to ErbB antibodies may be caused by nuclear localization of ErbB2 [9], miRNA production [10], higher Akt signaling, or steric hindrance by other membrane proteins [11] and raises the need for other therapeutic compounds useful in the treatment of ErbB overexpressing cancers. The gene discussed is AKT1; the disease is cancer.